Thierry Horner Selected Research

molibresib

1/2022	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
4/2020	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thierry Horner Research Topics

Disease

3	Neoplasms (Cancer) 01/2022 - 12/2019
2	Carcinoma (Carcinomatosis) 01/2022 - 04/2020
2	Nausea 01/2022 - 04/2020
2	Thrombocytopenia (Thrombopenia) 01/2022 - 04/2020
1	Triple Negative Breast Neoplasms 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022
1	Fatigue 04/2020
1	Diarrhea 04/2020
1	Anemia 04/2020
1	Vomiting 04/2020
1	Dysgeusia (Parageusia) 04/2020

Drug/Important Bio-Agent (IBA)

2	molibresibIBA 01/2022 - 04/2020
2	Nuclear Proteins (Protein, Nuclear)IBA 01/2022 - 04/2020
1	Estrogen ReceptorsIBA 01/2022
1	GSK-2816126IBA 12/2019
1	Enhancer of Zeste Homolog 2 ProteinIBA 12/2019

Therapy/Procedure

1	Drug Tapering 01/2022
1	Castration 01/2022